Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Atlas Arteria

ASX:ALX
Snowflake Description

Moderate growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALX
ASX
A$4B
Market Cap
  1. Home
  2. AU
  3. Transportation
Company description

Atlas Arteria Limited owns, develops, and operates toll roads. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Atlas Arteria has significant price volatility in the past 3 months.
ALX Share Price and Events
7 Day Returns
-6%
ASX:ALX
-6.3%
AU Infrastructure
5%
AU Market
1 Year Returns
-28.9%
ASX:ALX
-17.9%
AU Infrastructure
-19.2%
AU Market
ALX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Atlas Arteria (ALX) -6% -37.3% -36.7% -28.9% -2.7% 50.2%
AU Infrastructure -6.3% -29.1% -28.6% -17.9% -7.4% 11.2%
AU Market 5% -20.3% -25.8% -19.2% -16.8% -17.5%
1 Year Return vs Industry and Market
  • ALX underperformed the Infrastructure industry which returned -17.9% over the past year.
  • ALX underperformed the Market in Australia which returned -19.2% over the past year.
Price Volatility
ALX
Industry
5yr Volatility vs Market

Value

 Is Atlas Arteria undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Atlas Arteria to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Atlas Arteria.

ASX:ALX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 3 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.2%
Perpetual Growth Rate 10-Year AU Government Bond Rate 1.1%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:ALX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 1.1%
Equity Risk Premium S&P Global 5.4%
Infrastructure Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.669 (1 + (1- 30%) (50.31%))
0.936
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.94
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.08% + (0.936 * 5.44%)
6.17%

Discounted Cash Flow Calculation for ASX:ALX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Atlas Arteria is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

ASX:ALX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 6.17%)
2020 350.78 Analyst x1 330.38
2021 632.53 Analyst x1 561.11
2022 868.15 Est @ 37.25% 725.35
2023 1,097.33 Est @ 26.4% 863.52
2024 1,303.67 Est @ 18.8% 966.25
2025 1,479.49 Est @ 13.49% 1,032.80
2026 1,623.96 Est @ 9.76% 1,067.73
2027 1,740.22 Est @ 7.16% 1,077.65
2028 1,833.07 Est @ 5.34% 1,069.14
2029 1,907.47 Est @ 4.06% 1,047.85
Present value of next 10 years cash flows A$8,741.00
ASX:ALX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$1,907.47 × (1 + 1.08%) ÷ (6.17% – 1.08%)
A$37,853.65
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$37,853.65 ÷ (1 + 6.17%)10
A$20,794.40
ASX:ALX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$8,741.00 + A$20,794.40
A$29,535.40
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$29,535.40 / 879.02
A$33.6
ASX:ALX Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$33.60
Current discount Discount to share price of A$5.00
= -1 x (A$5.00 - A$33.60) / A$33.60
85.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Atlas Arteria is available for.
Intrinsic value
>50%
Share price is A$5 vs Future cash flow value of A$33.6
Current Discount Checks
For Atlas Arteria to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Atlas Arteria's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Atlas Arteria's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Atlas Arteria's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Atlas Arteria's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:ALX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in AUD A$0.02
ASX:ALX Share Price ** ASX (2020-04-03) in AUD A$5
Oceania Infrastructure Industry PE Ratio Median Figure of 8 Publicly-Listed Infrastructure Companies 31.65x
Australia Market PE Ratio Median Figure of 515 Publicly-Listed Companies 12.99x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Atlas Arteria.

ASX:ALX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:ALX Share Price ÷ EPS (both in AUD)

= 5 ÷ 0.02

204.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atlas Arteria is overvalued based on earnings compared to the Oceania Infrastructure industry average.
  • Atlas Arteria is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does Atlas Arteria's expected growth come at a high price?
Raw Data
ASX:ALX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 204.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
52.5%per year
Oceania Infrastructure Industry PEG Ratio Median Figure of 6 Publicly-Listed Infrastructure Companies 3.07x
Australia Market PEG Ratio Median Figure of 336 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

ASX:ALX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 204.36x ÷ 52.5%

3.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atlas Arteria is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Atlas Arteria's assets?
Raw Data
ASX:ALX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in AUD A$3.87
ASX:ALX Share Price * ASX (2020-04-03) in AUD A$5
Australia Infrastructure Industry PB Ratio Median Figure of 5 Publicly-Listed Infrastructure Companies 1.17x
Australia Market PB Ratio Median Figure of 1,614 Publicly-Listed Companies 1.24x
ASX:ALX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:ALX Share Price ÷ Book Value per Share (both in AUD)

= 5 ÷ 3.87

1.29x

* Primary Listing of Atlas Arteria.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Atlas Arteria is overvalued based on assets compared to the AU Infrastructure industry average.
X
Value checks
We assess Atlas Arteria's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Infrastructure industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Infrastructure industry average (and greater than 0)? (1 check)
  5. Atlas Arteria has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Atlas Arteria expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Atlas Arteria expected to grow at an attractive rate?
  • Atlas Arteria's earnings growth is expected to exceed the low risk savings rate of 1.1%.
Growth vs Market Checks
  • Atlas Arteria's earnings growth is expected to exceed the Australia market average.
  • Atlas Arteria's revenue growth is positive but not above the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:ALX Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:ALX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 52.5%
ASX:ALX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 3.3%
Oceania Infrastructure Industry Earnings Growth Rate Market Cap Weighted Average 37.2%
Oceania Infrastructure Industry Revenue Growth Rate Market Cap Weighted Average 4%
Australia Market Earnings Growth Rate Market Cap Weighted Average 10.2%
Australia Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:ALX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:ALX Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 187 561 456 3
2021-12-31 177 590 412 3
2020-12-31 154 473 233 3
2020-04-04
ASX:ALX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-12-31 175 76 17
2019-09-30 167 56 17
2019-06-30 159 35 18
2019-03-31 146 29 47
2018-12-31 132 23 77
2018-09-30 126 34 78
2018-06-30 120 46 78
2018-03-31 101 32 270
2017-12-31 83 18 462
2017-09-30 54 -4 506
2017-06-30 25 -25 550
2017-03-31 14 -20 388

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Atlas Arteria's earnings are expected to grow significantly at over 20% yearly.
  • Atlas Arteria's revenue is expected to grow by 3.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:ALX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Atlas Arteria Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALX Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.47 0.57 0.35 3.00
2021-12-31 0.43 0.52 0.31 4.00
2020-12-31 0.26 0.48 0.04 4.00
2020-04-04
ASX:ALX Past Financials Data
Date (Data in AUD Millions) EPS *
2019-12-31 0.02
2019-09-30 0.02
2019-06-30 0.02
2019-03-31 0.06
2018-12-31 0.11
2018-09-30 0.14
2018-06-30 0.17
2018-03-31 0.52
2017-12-31 0.78
2017-09-30 0.92
2017-06-30 1.09
2017-03-31 0.75

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Atlas Arteria is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Atlas Arteria's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Oceania market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Oceania market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Atlas Arteria has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Atlas Arteria performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Atlas Arteria's growth in the last year to its industry (Infrastructure).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Atlas Arteria's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Atlas Arteria's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Atlas Arteria's 1-year earnings growth is negative, it can't be compared to the Oceania Infrastructure industry average.
Earnings and Revenue History
Atlas Arteria's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Atlas Arteria Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:ALX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 175.19 17.08 33.89
2019-09-30 167.03 17.34 39.71
2019-06-30 158.88 17.60 45.53
2019-03-31 145.63 47.14 82.41
2018-12-31 132.38 76.68 119.30
2018-09-30 126.02 77.53 117.50
2018-06-30 119.66 78.37 115.70
2018-03-31 101.44 270.28 82.05
2017-12-31 83.23 462.20 48.41
2017-09-30 53.87 506.18 13.26
2017-06-30 24.51 550.15 -21.89
2017-03-31 13.60 387.63 39.76
2016-12-31 2.69 225.11 101.40
2016-09-30 2.27 162.04 134.31
2016-06-30 1.84 98.97 167.22
2016-03-31 2.03 92.03 98.28
2015-12-31 2.21 85.08 29.34
2015-09-30 2.52 71.35 27.42
2015-06-30 2.83 57.62 25.50
2015-03-31 2.48 3.53 54.21
2014-12-31 2.12 -50.56 82.92
2014-06-30 1.71 -47.41 83.27
2014-03-31 1.30 -2.74 52.73
2013-12-31 0.89 41.93 22.20
2013-06-30 0.25 5.08 17.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Atlas Arteria has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • Atlas Arteria used its assets less efficiently than the Oceania Infrastructure industry average last year based on Return on Assets.
  • It is difficult to establish if Atlas Arteria improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Atlas Arteria's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Infrastructure industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Atlas Arteria has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Atlas Arteria's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Atlas Arteria's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Atlas Arteria is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Atlas Arteria's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Atlas Arteria's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Atlas Arteria Company Filings, last reported 3 months ago.

ASX:ALX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 3,403.03 2,190.50 1,450.22
2019-09-30 3,403.03 2,190.50 1,450.22
2019-06-30 2,138.69 2,148.40 150.99
2019-03-31 2,138.69 2,148.40 150.99
2018-12-31 2,328.51 2,195.89 186.47
2018-09-30 2,328.51 2,195.89 186.47
2018-06-30 2,152.60 1,873.54 155.96
2018-03-31 2,152.60 1,873.54 155.96
2017-12-31 2,162.08 1,734.64 122.69
2017-09-30 2,162.08 1,734.64 122.69
2017-06-30 1,621.17 1,498.60 122.55
2017-03-31 1,621.17 1,498.60 122.55
2016-12-31 1,073.00 0.00 223.37
2016-09-30 1,073.00 0.00 223.37
2016-06-30 859.67 0.00 221.04
2016-03-31 859.67 0.00 221.04
2015-12-31 864.96 0.00 65.38
2015-09-30 864.96 0.00 65.38
2015-06-30 816.50 0.00 43.74
2015-03-31 816.50 0.00 43.74
2014-12-31 822.89 0.00 30.12
2014-06-30 734.86 0.00 21.99
2014-03-31 734.86 0.00 21.99
2013-12-31 875.56 0.00 17.66
2013-06-30 798.15 0.00 16.90
  • Atlas Arteria's level of debt (64.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if Atlas Arteria's debt level has increased without past 5-year debt data.
  • Debt is not well covered by operating cash flow (3.5%, less than 20% of total debt).
  • Unable to confirm if the interest payments on Atlas Arteria's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Atlas Arteria's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Atlas Arteria has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Atlas Arteria's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Atlas Arteria dividends. Estimated to be 6.55% next year.
If you bought A$2,000 of Atlas Arteria shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Atlas Arteria's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Atlas Arteria's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:ALX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Oceania Infrastructure Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 2.8%
Australia Market Average Dividend Yield Market Cap Weighted Average of 367 Stocks 5.5%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.7%
Australia Bottom 25% Dividend Yield 25th Percentile 3.2%
Australia Top 25% Dividend Yield 75th Percentile 8.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:ALX Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.45 7.00
2021-12-31 0.35 8.00
2020-12-31 0.20 8.00
2020-04-04
ASX:ALX Past Annualized Dividends Data
Date (Data in A$) Dividend per share (annual) Avg. Yield (%)
2020-03-23 0.000 0.000
2020-02-26 0.360 5.437
2019-03-18 0.300 3.861
2019-02-28 0.300 4.285
2019-02-27 0.300 4.213
2018-09-17 0.240 3.598
2018-03-28 0.240 3.725
2017-09-13 0.200 3.463
2017-03-23 0.190 3.386
2016-09-15 0.180 3.755
2016-03-10 0.190 3.662
2015-09-14 0.160 3.939
2015-02-25 0.164 4.936
2014-03-11 0.100 3.196
2013-09-11 0.066 2.483
2013-03-20 0.048 2.480

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Atlas Arteria has not reported any payouts.
  • Unable to verify if Atlas Arteria's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Atlas Arteria's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Atlas Arteria has not reported any payouts.
Future Payout to shareholders
  • Dividends after 3 years are not well covered by earnings (1x coverage).
X
Income/ dividend checks
We assess Atlas Arteria's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.7%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Atlas Arteria afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Atlas Arteria has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Atlas Arteria's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Graeme Bevans
COMPENSATION A$2,747,183
AGE 61
TENURE AS CEO 1 years
CEO Bio

Mr. Graeme Francis Bevans serves as Managing Director, Chief Executive Officer and Director at Atlas Arteria Limited since April 1, 2019. Mr. Bevans was a Partner at Alinda Capital Partners LLC since 2010. Mr. Bevans focused on Infrastructure investments. Mr. Bevans has over 20 years’ experience in infrastructure. He has over 25 years of international experience in corporate banking and infrastructure investing. Prior to that, he served as a Vice President and Head of Infrastructure Investing at Canada Pension Plan Investment Board. Mr. Bevans was responsible for leading the development of the infrastructure portfolio in the private investments department. Mr. Bevans served as the Head of Infrastructure Investing at Industry Funds Management Pty Ltd. (IFM). Previously, he served as a Director of Capital Markets at AIDC, working extensively in Asia, Europe and the United States. Mr. Bevans served as an Executive Director at Copernican Securities Pty Ltd, where he advised on infrastructure investment financing. He served as a Director of Osprey Holdco Ltd. He served as Head of Infrastructure Investing at IFM Investors Pty Ltd. He served as Non-Executive Director of AWG Plc until July 28, 2010. Mr. Bevans served as a Director of Broadcast Australia Pty Limited since July 2009. He served as a Director of Puget Sound Energy Inc., and of Puget Energy Inc. from February 6, 2009 to July 2010. Mr. Bevans served as a Director of Guardian Digital Communications Ltd from July 21, 2009 to July 31, 2010. He served as a Director of Anglian Water Group Limited until July 28, 2010. Mr. Bevans was a Non-Executive Director of Pacific Hydro Ltd. since August 2, 2004.

CEO Compensation
  • Graeme's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Graeme's remuneration is lower than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Atlas Arteria management team in years:

1
Average Tenure
  • The average tenure for the Atlas Arteria management team is less than 2 years, this suggests a new team.
Management Team

Graeme Bevans

TITLE
MD, CEO & Director
COMPENSATION
A$3M
AGE
61
TENURE
1 yrs

Nadine Lennie

TITLE
Chief Financial Officer
COMPENSATION
A$1M
AGE
46
TENURE
1 yrs

Vincent Portal-Barrault

TITLE
Chief Operating Officer
COMPENSATION
A$1M
TENURE
1 yrs

Phillipa Chen

TITLE
Head of Investor Relations

Clayton McCormack

TITLE
Company Secretary & General Counsel
TENURE
1 yrs

Navleen Prasad

TITLE
Public Affairs Manager
Board of Directors Tenure

Average tenure and age of the Atlas Arteria board of directors in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Atlas Arteria board of directors is less than 3 years, this suggests a new board.
Board of Directors

NL Scheinkestel

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$290K
AGE
59
TENURE
5 yrs

Graeme Bevans

TITLE
MD, CEO & Director
COMPENSATION
A$3M
AGE
61
TENURE
1 yrs

Debbie Goodin

TITLE
Independent Non-Executive Director
COMPENSATION
A$208K
AGE
52
TENURE
2.6 yrs

David Bartholomew

TITLE
Independent Non Executive Director
COMPENSATION
A$188K
AGE
58
TENURE
1.5 yrs

Jean-Georges Malcor

TITLE
Independent Non-Executive Director
COMPENSATION
A$185K
AGE
63
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Atlas Arteria individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
25. Aug 19 Sell DWS Investment S.A. Company 25. Sep 18 21. Aug 19 -986,219 A$8.19 A$0
20. Mar 20 Buy Jean-Georges Malcor Individual 16. Mar 20 16. Mar 20 5,000 A$5.57 A$27,850
20. Mar 20 Buy James Keyes Individual 13. Mar 20 13. Mar 20 12,000 A$5.75 A$69,000
15. Mar 20 Buy Debra Goodin Individual 13. Mar 20 13. Mar 20 1,487 A$5.71 A$8,491
15. Mar 20 Buy Graeme Bevans Individual 13. Mar 20 13. Mar 20 10,000 A$5.82 A$58,220
13. Mar 20 Buy Jeffrey Conyers Individual 13. Mar 20 13. Mar 20 5,000 A$5.67 A$28,350
13. Mar 20 Buy Jeffrey Conyers Individual 12. Mar 20 12. Mar 20 7,619 A$6.43 A$48,990
13. Mar 20 Buy Fiona Beck Individual 13. Mar 20 13. Mar 20 7,000 A$5.77 A$40,390
31. Jan 20 Sell Magellan Asset Management Limited Company 16. Dec 19 29. Jan 20 -8,406,194 A$8.10 A$-68,132,039
31. Jan 20 Buy Magellan Asset Management Limited Company 16. Dec 19 14. Jan 20 936,872 A$7.65 A$7,166,802
15. Jan 20 Sell Yarra Funds Management Limited Company 08. Aug 19 13. Jan 20 -4,902,389 A$7.97 A$-39,090,181
15. Jan 20 Buy Yarra Funds Management Limited Company 08. Aug 19 13. Jan 20 8,751,818 A$7.11 A$62,214,358
23. Dec 19 Buy Derek Stapley Individual 16. Dec 19 16. Dec 19 4,266 A$6.90 A$29,435
23. Dec 19 Buy James Keyes Individual 16. Dec 19 16. Dec 19 952 A$6.90 A$6,569
20. Dec 19 Buy Fiona Beck Individual 16. Dec 19 16. Dec 19 1,333 A$6.90 A$9,198
20. Dec 19 Buy Nora Scheinkestel Individual 16. Dec 19 16. Dec 19 16,613 A$6.90 A$114,630
20. Dec 19 Buy Jean-Georges Malcor Individual 16. Dec 19 16. Dec 19 3,238 A$6.90 A$22,342
20. Dec 19 Buy Debra Goodin Individual 16. Dec 19 16. Dec 19 3,838 A$6.90 A$26,482
20. Dec 19 Buy David Bartholomew Individual 16. Dec 19 16. Dec 19 1,663 A$6.90 A$11,475
20. Dec 19 Buy Graeme Bevans Individual 16. Dec 19 16. Dec 19 14,517 A$6.90 A$100,167
19. Dec 19 Sell Lazard Asset Management LLC Company 24. Oct 19 04. Dec 19 -6,472,096 A$8.32 A$-48,923,070
19. Dec 19 Buy Lazard Asset Management LLC Company 23. Oct 19 17. Dec 19 22,775,791 A$8.40 A$163,118,880
17. Dec 19 Sell Magellan Asset Management Limited Company 02. Jul 19 27. Nov 19 -620,432 A$8.04 A$-4,987,018
17. Dec 19 Buy Magellan Asset Management Limited Company 26. Jun 19 13. Dec 19 19,702,789 A$7.32 A$144,183,961
10. Dec 19 Buy Jeffrey Conyers Individual 04. Dec 19 04. Dec 19 2,381 A$7.45 A$17,738
02. Dec 19 Buy David Bartholomew Individual 26. Nov 19 26. Nov 19 10,113 A$7.91 A$79,994
02. Dec 19 Buy Debra Goodin Individual 29. Nov 19 29. Nov 19 2,594 A$7.70 A$19,974
24. Oct 19 Buy Lazard Asset Management LLC Company 26. Sep 19 22. Oct 19 6,883,679 A$8.30 A$54,574,557
27. Sep 19 Buy Lazard Asset Management LLC Company 28. Aug 19 25. Sep 19 7,652,699 A$8.60 A$63,744,248
25. Sep 19 Buy Fiona Beck Individual 23. Sep 19 23. Sep 19 7,000 A$7.93 A$55,496
06. Sep 19 Buy Nora Scheinkestel Individual 02. Sep 19 02. Sep 19 5,913 A$8.44 A$49,901
06. Sep 19 Buy Derek Stapley Individual 02. Sep 19 02. Sep 19 17,400 A$8.50 A$147,900
28. Aug 19 Sell Lazard Asset Management LLC Company 03. Jul 18 20. Aug 19 -17,416,357 A$6.98 A$-121,600,664
28. Aug 19 Buy Lazard Asset Management LLC Company 13. Jul 18 26. Aug 19 25,430,686 A$7.50 A$190,727,927
25. Aug 19 Sell DBX Advisors LLC Company 24. Sep 18 07. Aug 19 -5,719 A$8.21 A$0
25. Aug 19 Sell Deutsche Bank, Private Banking and Investment Banking Investments Company 26. Sep 18 21. Aug 19 -5,771,303 A$8.43 A$0
25. Aug 19 Buy Deutsche Bank, Private Banking and Investment Banking Investments Company 21. Sep 18 15. Aug 19 5,306,030 A$8.44 A$0
25. Aug 19 Sell RREEF America L.L.C. Company 20. Sep 18 21. Aug 19 -8,599,507 A$8.22 A$-48,631
25. Aug 19 Buy RREEF America L.L.C. Company 20. Sep 18 31. May 19 2,060,997 A$7.13 A$43,547
09. Aug 19 Buy Yarra Funds Management Limited Company 09. Apr 19 07. Aug 19 559,382 A$7.74 A$4,326,966
15. Jul 19 Sell Macquarie Group, Ltd., Banking & Securities Investments Company 02. May 19 10. Jul 19 -1,573,938 A$8.19 A$0
15. Jul 19 Buy Macquarie Group, Ltd., Banking & Securities Investments Company 02. May 19 10. Jul 19 1,273,573 A$8.26 A$0
15. Jul 19 Sell Macquarie Capital Investment Management LLC Company 10. May 19 10. Jul 19 -1,286,004 A$7.97 A$0
15. Jul 19 Buy Macquarie Capital Investment Management LLC Company 17. May 19 19. Jun 19 60,631 A$7.99 A$280,976
15. Jul 19 Sell Macquarie Investment Management Limited Company 02. May 19 04. Jul 19 -25,726 A$8.12 A$0
15. Jul 19 Buy Macquarie Investment Management Limited Company 02. May 19 04. Jul 19 25,726 A$8.12 A$0
15. Jul 19 Sell Macquarie Investment Management Limited Company 02. May 19 10. Jul 19 -2,268,978 A$11.41 A$-17,355
15. Jul 19 Buy Macquarie Investment Management Limited Company 02. May 19 10. Jul 19 2,647,699 A$10.56 A$39,357
09. Jul 19 Sell Yarra Funds Management Limited Company 05. Dec 17 05. Jul 19 -22,327,528 A$6.86 A$-153,246,627
09. Jul 19 Buy Yarra Funds Management Limited Company 05. Dec 17 05. Jul 19 14,728,243 A$6.34 A$93,375,568
26. Jun 19 Sell Magellan Asset Management Limited Company 12. Oct 18 11. Jun 19 -892,843 A$6.56 A$-5,858,831
26. Jun 19 Buy Magellan Asset Management Limited Company 08. Oct 18 24. Jun 19 7,834,606 A$6.95 A$54,483,034
30. May 19 Sell FIL Limited Company 11. Apr 19 28. May 19 -2,031,331 A$7.33 A$0
30. May 19 Buy FIL Limited Company 24. Apr 19 13. May 19 294,750 A$7.26 A$0
06. May 19 Sell Macquarie Group, Ltd., Banking & Securities Investments Company 14. Feb 19 01. May 19 -369,025 A$7.32 A$0
06. May 19 Buy Macquarie Group, Ltd., Banking & Securities Investments Company 14. Feb 19 01. May 19 759,091 A$7.27 A$0
06. May 19 Sell Macquarie Capital Investment Management LLC Company 22. Feb 19 26. Apr 19 -2,087,842 A$7.26 A$0
06. May 19 Buy Macquarie Capital Investment Management LLC Company 15. Mar 19 26. Apr 19 182,872 A$7.10 A$150,431
06. May 19 Sell Macquarie Investment Management Limited Company 14. Feb 19 24. Apr 19 -3,519,440 A$7.30 A$0
06. May 19 Buy Macquarie Investment Management Limited Company 14. Feb 19 24. Apr 19 3,519,440 A$7.30 A$0
06. May 19 Sell Macquarie Investment Management Limited Company 14. Feb 19 01. May 19 -3,668,978 A$7.33 A$0
06. May 19 Buy Macquarie Investment Management Limited Company 14. Feb 19 01. May 19 3,768,453 A$9.97 A$212,536
X
Management checks
We assess Atlas Arteria's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Atlas Arteria has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Does It Make Sense To Buy Atlas Arteria Limited (ASX:ALX) For Its Yield?

Dividend paying stocks like Atlas Arteria Limited (ASX:ALX) tend to be popular with investors, and for good reason - some research suggests a significant amount of all stock market returns come from reinvested dividends. … With a goodly-sized dividend yield despite a relatively short payment history, investors might be wondering if Atlas Arteria is a new dividend aristocrat in the making. … Dividend Growth Potential While dividend payments have been relatively reliable, it would also be nice if earnings per share (EPS) were growing, as this is essential to maintaining the dividend's purchasing power over the long term. Earnings have grown at around 5.4% a year for the past five years, which is better than seeing them shrink! Although per-share earnings are growing at a credible rate, virtually all of the income is being paid out as dividends to shareholders. This is okay, but may limit growth in the company's future dividend payments. We'd also point out that Atlas Arteria issued a meaningful number of new shares in the past year. Trying to grow the dividend when issuing new shares reminds us of the ancient Greek tale of Sisyphus - perpetually pushing a boulder uphill. Companies that consistently issue new shares are often suboptimal from a dividend perspective. Conclusion Dividend investors should always want to know if a) a company's dividends are affordable, b) if there is a track record of consistent payments, and c) if the dividend is capable of growing.

Simply Wall St -

Estimating The Intrinsic Value Of Atlas Arteria Limited (ASX:ALX)

In this article we are going to estimate the intrinsic value of Atlas Arteria Limited (ASX:ALX) by taking the expected future cash flows and discounting them to their present value. … Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 10-year free cash flow (FCF) forecast 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 Levered FCF (A$, Millions) A$387.6m A$410.2m A$429.7m A$447.1m A$462.8m A$477.4m A$491.2m A$504.6m A$517.7m A$530.8m Growth Rate Estimate Source Analyst x1 Est @ 5.82% Est @ 4.77% Est @ 4.03% Est @ 3.52% Est @ 3.16% Est @ 2.9% Est @ 2.73% Est @ 2.6% Est @ 2.51% Present Value (A$, Millions) Discounted @ 8.58% A$357.0 A$347.9 A$335.7 A$321.6 A$306.7 A$291.3 A$276.1 A$261.2 A$246.8 A$233.1 ("Est" = FCF growth rate estimated by Simply Wall St) Present Value of 10-year Cash Flow (PVCF)= A$3.0b We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. … ASX:ALX Intrinsic value, August 12th 2019 The assumptions Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows.

Simply Wall St -

Are Insiders Buying Atlas Arteria Limited (ASX:ALX) Stock?

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.' Check out our latest analysis for Atlas Arteria The Last 12 Months Of Insider Transactions At Atlas Arteria Independent Non-Executive Director Jean-Georges Malcor made the biggest insider purchase in the last 12 months. … While Atlas Arteria insiders bought shares last year, they didn't sell. … The transactions are fine but it'd be more encouraging if Atlas Arteria insiders bought more shares in the company.

Simply Wall St -

Should Atlas Arteria Limited (ASX:ALX) Focus On Improving This Fundamental Metric?

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Atlas Arteria: 2.6% = AU$77m ÷ AU$2.3b (Based on the trailing twelve months to December 2018.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … Does Atlas Arteria Have A Good Return On Equity? … Atlas Arteria's Debt And Its 2.6% ROE While Atlas Arteria does have some debt, with debt to equity of just 0.94, we wouldn't say debt is excessive.

Simply Wall St -

Investors Who Bought Atlas Arteria (ASX:ALX) Shares Five Years Ago Are Now Up 145%

For example, the Atlas Arteria Limited (ASX:ALX) share price has soared 145% in the last half decade. … During five years of share price growth, Atlas Arteria achieved compound earnings per share (EPS) growth of 5.4% per year. … Atlas Arteria is not the only stock that insiders are buying.

Simply Wall St -

Introducing Atlas Arteria (ASX:ALX), The Stock That Zoomed 145% In The Last Five Years

One great example is Atlas Arteria Limited (ASX:ALX) which saw its share price drive 145% higher over five years. … Over half a decade, Atlas Arteria managed to grow its earnings per share at 5.4% a year. … As it happens, Atlas Arteria's TSR for the last 5 years was 205%, which exceeds the share price return mentioned earlier.

Simply Wall St -

Is Atlas Arteria Limited's (ASX:ALX) Balance Sheet A Threat To Its Future?

View our latest analysis for Atlas Arteria ALX’s Debt (And Cash Flows) ALX's debt levels surged from AU$1.7b to AU$2.2b over the last 12 months , which accounts for long term debt. … On top of this, ALX has generated AU$23m in operating cash flow during the same period of time, leading to an operating cash to total debt ratio of 1.1%, signalling that ALX’s operating cash is less than its debt. … Next Steps: ALX’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Three Things You Should Check Before Buying Atlas Arteria Limited (ASX:ALX) For Its Dividend

In this case, Atlas Arteria likely looks attractive to dividend investors, given its 4.1% dividend yield and six-year payment history. … With a cash payout ratio of 386%, Atlas Arteria's dividend payments are poorly covered by cash flow. … Atlas Arteria has a low payout ratio, which we like, although it paid out virtually all of its generated cash.

Simply Wall St -

Are Investors Undervaluing Atlas Arteria Limited (ASX:ALX) By 28%?

In this article we are going to estimate the intrinsic value of Atlas Arteria Limited (ASX:ALX) by taking the expected future cash flows and discounting them to today's value. … We assume companies with shrinking free cash flow are will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. … Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) forecast 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Levered FCF (A$, Millions) A$292.62 A$316.57 A$384.00 A$438.44 A$484.99 A$524.40 A$557.87 A$586.66 A$611.92 A$634.61 Growth Rate Estimate Source Analyst x2 Analyst x2 Analyst x1 Est @ 14.18% Est @ 10.62% Est @ 8.13% Est @ 6.38% Est @ 5.16% Est @ 4.31% Est @ 3.71% Present Value (A$, Millions) Discounted @ 9.17% A$268.05 A$265.65 A$295.18 A$308.73 A$312.84 A$309.86 A$301.96 A$290.88 A$277.93 A$264.04 Present Value of 10-year Cash Flow (PVCF)= A$2.90b "Est" = FCF growth rate estimated by Simply Wall St We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period.

Simply Wall St -

What Investors Should Know About Atlas Arteria Limited's (ASX:ALX) Financial Strength

However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is. … Let's work through some financial health checks you may wish to consider if you're interested in this stock.

Simply Wall St -

Company Info

Description

Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in TRIP II, the concessionaire for Dulles Greenway toll road located in northern Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.

Details
Name: Atlas Arteria Limited
ALX
Exchange: ASX
Founded: 2009
A$4,395,122,440
879,024,488
Website: http://www.atlasarteria.com
Address: Atlas Arteria Limited
141 Flinders Lane,
Level 5,
Melbourne,
Victoria, 3000,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX ALX Stapled Securities Australian Securities Exchange AU AUD 25. Jan 2010
OTCPK MAQA.F Stapled Securities Pink Sheets LLC US USD 25. Jan 2010
DB M82 Stapled Securities Deutsche Boerse AG DE EUR 25. Jan 2010
CHIA ALX Stapled Securities Chi-X Australia AU AUD 25. Jan 2010
Number of employees
Current staff
Staff numbers
0
Atlas Arteria employees.
Industry
Highways and Railtracks
Transportation
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 10:46
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/30
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.